Literature DB >> 201214

Polymyxin B and rifampin: new regimen for multiresistant Serratia marcescens infections.

R C Ostenson, B T Fields, C M Nolan.   

Abstract

Polymyxin B and rifampin were given to 12 patients with multi-drug-resistant nosocomial Serratia marcescens infections. Eight cures were achieved; drug hepatotoxicity occurred once; one fatal suprainfection was encountered; and two patients died during therapy of causes related to severe underlying illnesses. Polymyxin B and rifampin were uniformly synergistic in vitro against the infecting strains and against 40 additional clinical isolates of S. marcescens.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 201214      PMCID： PMC429999          DOI： 10.1128/AAC.12.6.655

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  In vitro additive effect of polymxin B and rifampin against Serratia marcesen.

Authors:  W H Traub; I Kleber
Journal:  Antimicrob Agents Chemother       Date:  1975-06       Impact factor: 5.191

Review 2.  The polymyxins.

Authors:  P D Hoeprich
Journal:  Med Clin North Am       Date:  1970-09       Impact factor: 5.456

3.  Bacterial colonization and clinical superinfection of the respiratory tract complicating antibiotic treatment of pneumonia.

Authors:  J R Tillotson; M Finland
Journal:  J Infect Dis       Date:  1969-06       Impact factor: 5.226

4.  Amikacin therapy for severe gram-negative sepsis. Emphasis on infections with gentamicin-resistant organisms.

Authors:  F P Tally; T J Louie; W M Weinstein; J G Bartlett; S L Gorbach
Journal:  Ann Intern Med       Date:  1975-10       Impact factor: 25.391

5.  Amikacin resistance developing in patients with Pseudomonas aeruginosa bronchopneumonia.

Authors:  I D Amirak; R J Williams; P Noone; M R Wills
Journal:  Lancet       Date:  1977-03-05       Impact factor: 79.321

6.  Sulfamethoxazole-trimethoprim-polymyxin therapy of serious multiply drug-resistant Serratia infections.

Authors:  F E Thomas; J M Leonard; R H Alford
Journal:  Antimicrob Agents Chemother       Date:  1976-02       Impact factor: 5.191

7.  Amikacin therapy of patients with multiply antibiotic-resistant Serratia marcescens infections: development of increasing resistance during therapy.

Authors:  P C Craven; J H Jorgensen; R L Kaspar; D J Drutz
Journal:  Am J Med       Date:  1977-06       Impact factor: 4.965

8.  Comparison of methods for assessing in vitro antibiotic synergism against Pseudomonas and Serratia.

Authors:  R J Weinstein; L S Young; W L Hewitt
Journal:  J Lab Clin Med       Date:  1975-11

9.  Gentamicin-resistant Pseudomonas aeruginosa and Serratia marcescens in a general hospital.

Authors:  R D Meyer; R P Lewis; J Halter; M White
Journal:  Lancet       Date:  1976-03-13       Impact factor: 79.321

10.  Detection of Serratia outbreaks in hospital.

Authors:  J J Farmer; B R Davis; F W Hickman; D B Presley; G P Bodey; M Negut; R A Bobo
Journal:  Lancet       Date:  1976-08-28       Impact factor: 79.321
View more
  12 in total

1.  In vitro double and triple synergistic activities of Polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii.

Authors:  Jimmy Yoon; Carl Urban; Christian Terzian; Noriel Mariano; James J Rahal
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

2.  In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli.

Authors:  Carl Urban; Noriel Mariano; James J Rahal
Journal:  Antimicrob Agents Chemother       Date:  2010-04-05       Impact factor: 5.191

Review 3.  Polymyxins revisited.

Authors:  David Landman; Claudiu Georgescu; Don Antonio Martin; John Quale
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

4.  The use of intravenous colistin among children in the United States: results from a multicenter, case series.

Authors:  Pranita D Tamma; Jason G Newland; Pia S Pannaraj; Talene A Metjian; Ritu Banerjee; Jeffrey S Gerber; Scott J Weissman; Susan E Beekmann; Philip M Polgreen; Adam L Hersh
Journal:  Pediatr Infect Dis J       Date:  2013-01       Impact factor: 2.129

5.  Activity of the colistin-rifampicin combination against colistin-resistant, carbapenemase-producing Gram-negative bacteria.

Authors:  Marcela Nastro; Carlos Hernan Rodríguez; Renata Monge; Jonathan Zintgraff; Liliana Neira; Mirta Rebollo; Carlos Vay; Angela Famiglietti
Journal:  J Chemother       Date:  2013-12-06       Impact factor: 1.714

6.  Susceptibility of Pseudomonas maltophilia to antimicrobial agents, singly and in combination.

Authors:  T P Felegie; V L Yu; L W Rumans; R B Yee
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

7.  Comparative susceptibilities of Pseudomonas aeruginosa to 1-oxacephalosporin (LY 127935) and eight other antipseudomonal antimicrobial agents (old and new).

Authors:  V L Yu; R M Vickers; J J Zuravleff
Journal:  Antimicrob Agents Chemother       Date:  1980-01       Impact factor: 5.191

8.  Comparative susceptibilities of clinical isolates of Serratia marcescens to newer cephalosporins, alone and in combination with various aminoglycosides.

Authors:  S M Markowitz; D J Sibilla
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

9.  Effect of calcium, magnesium, and zinc on ticarcillin and tobramycin alone and in combination against Pseudomonas aeruginosa.

Authors:  J J Zuravleff; V L Yu; R B Yee; M K Zaphyr; W Diven; F B Taylor
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

Review 10.  The role of carbapenems in initial therapy for serious Gram-negative infections.

Authors:  James J Rahal
Journal:  Crit Care       Date:  2008-05-21       Impact factor: 9.097
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.